MRTX 1133
Alternative Names: MRTX-1133Latest Information Update: 09 Jun 2025
At a glance
- Originator Array BioPharma; Mirati Therapeutics
- Developer Mirati Therapeutics; University of Alabama at Birmingham
- Class Antineoplastics; Azabicyclo compounds; Cyclic hydrocarbons; Ethers; Fluorinated hydrocarbons; Naphthols; Pyridines; Pyrimidines; Pyrrolidines; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Multiple myeloma; Pancreatic cancer
- No development reported Cancer
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 03 Apr 2025 Mirati Therapeutics terminates a phase I/II trial in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in USA (PO) due to formulation challenges (NCT05737706)